Sodime

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sodime

Property Description
Active Ingredient Ceftazidime
Form Sterile Powder for Injection
Pharmacological Class Third-Generation Cephalosporin (Antibiotic)
Common Use Severe Systemic Bacterial Infections
Origin Synthetic / Semi-synthetic

Sodime is a potent prescription-only medicine (POM) whose sole active ingredient is Ceftazidime, a compound essential for treating serious bacterial infections within a clinical setting. It is classified as an antibiotic belonging to the third-generation cephalosporin family, recognized for its specific structural and chemical properties.


What Type of Medicine is Sodime? (Identity and Classification)

Sodime is a member of the extensive beta-lactam antibiotic group, which acts by disrupting the structural integrity of the bacterial cell. Ceftazidime's classification as a third-generation cephalosporin provides reliable coverage against difficult-to-treat Gram-negative bacteria, including the clinically significant Pseudomonas aeruginosa. This means the drug is effective against severe pathogens that may be resistant to older, more common antibiotics. The active compound is synthetic, having been designed to possess these properties that overcome microbial defenses. The specific formulation under the trade name Sodime is clinically recognized for its consistency in reconstitution and stability.


What is Sodime Made Of and How is it Supplied? (Composition and Form)

The drug is supplied as a sterile powder for injection, containing the active substance Ceftazidime (frequently as Ceftazidime Pentahydrate). Because the substance is not efficiently absorbed by the digestive system, it requires parenteral administration via intravenous (IV) or intramuscular (IM) injection after being properly reconstituted by a healthcare professional. This method of delivery is critical for ensuring the medication reaches the concentrations needed in the bloodstream to manage acute systemic infections. The sterile powder format defines its application for severe hospitalized patient populations.


What is the General Purpose of Ceftazidime? (Mechanism and Benefit)

The ultimate purpose of Sodime is to fight and eliminate severe systemic bacterial infections, such as those that might arise in critical care or surgical recovery. Functionally, it is a bactericidal agent, working by blocking the final stages of bacterial cell wall synthesis. By destroying the bacterial structures, the medicine stops the infection from spreading and allows the patient's immune system to clear the disease.

Regulatory References

  1. FDA Drug Label

What side effects are possible with Sodime?

Sodime's safety profile, based on official regulatory documentation, is structured around adverse reactions classified by the affected body system and frequency of occurrence in clinical trials.


Adverse Reaction Profile

Adverse reactions are documented across several System-Organ Classes, including Blood and Lymphatic System Disorders, Nervous System Disorders, Gastrointestinal Disorders, and Renal and Urinary Disorders. The most frequent grouping of effects, such as hypersensitivity reactions, gastrointestinal symptoms, and central nervous system reactions, was reported in less than 2% of patients during formal clinical studies.

Serious Adverse Reactions officially listed include Anaphylaxis and severe Neurologic Adverse Reactions such as encephalopathy, myoclonus, and seizures. The potential for Clostridium difficile-associated diarrhea (CDAD), which may progress to fatal colitis, is also a documented safety risk associated with systemic antibacterial agents.


Safety Constraints and Population Considerations

The medicine is contraindicated in individuals with a known serious hypersensitivity to ceftazidime, other cephalosporin class antibacterials, penicillins, or other beta-lactam antibacterials. This foundational constraint dictates appropriate patient selection.

Safety considerations for specific populations are detailed in the official label, particularly for patients with Renal Impairment. Because the drug is primarily eliminated by the kidneys, reduced renal function increases the risk of serious Neurologic Adverse Reactions. Official documentation also notes that the drug may be associated with high-level safety consequences like prolonged prothrombin time.

Overdose and Emergency Response

Overdose and When to Seek Help

This section details the officially documented manifestations and required emergency procedures for a Sodime (Ceftazidime) overdose, as strictly defined in government regulatory documents.


Documented Overdose Manifestations

An acute overdosage of Sodime is primarily associated with Central Nervous System (CNS) toxicity, potentially resulting in severe and even life-threatening neurological adverse reactions. Manifestations documented in regulatory labeling include:

  • Seizures (or convulsions)
  • Encephalopathy (brain disorder)
  • Myoclonus (involuntary muscle jerking)
  • Coma
  • Tremors, confusion, and muscle stiffness

When to Seek Immediate Medical Attention

Immediate medical attention is required upon suspicion or occurrence of an acute overdosage. Patients who receive an overdosage should be carefully observed and provided with supportive treatment.

A specific risk factor is impaired renal function (kidney failure). Because Ceftazidime is eliminated almost solely by the kidneys, patients with existing renal impairment are documented to be at an increased risk for these severe neurological adverse reactions.


Management Procedures

The regulatory information states that management involves administering supportive treatment. Additionally, hemodialysis or peritoneal dialysis may be employed to aid in the removal of Ceftazidime from the body, particularly in cases where kidney function is compromised.

Therapeutic Uses of Sodime

What Sodime Treats: Main Uses and Benefits

Sodime is a medication primarily utilized in the management of edema and certain forms of hypertension. It belongs to a class of drugs that assist the kidneys in managing fluid levels within the body.

Therapeutic Uses

The primary applications for Sodime include:

  • Management of Edema: It is used to treat fluid retention (edema) associated with congestive heart failure, hepatic cirrhosis, and renal disease. By promoting the excretion of excess water and salt, it helps reduce swelling in the limbs and abdomen.
  • Treatment of Hypertension: Sodime is prescribed for the management of high blood pressure. Lowering blood pressure is a critical step in reducing the risk of cardiovascular complications such as strokes and myocardial infarctions.
  • Acute Fluid Management: In clinical settings, it may be used to address acute pulmonary edema, where rapid removal of fluid from the lungs is necessary for respiratory function.

Mechanism of Action

Sodime functions by inhibiting the reabsorption of sodium and chloride in the kidneys, specifically within the loop of Henle and the distal renal tubules. This process increases the production of urine (diuresis). As the body eliminates more salt and water, the total volume of fluid circulating in the blood vessels decreases, which consequently lowers blood pressure and reduces the accumulation of fluid in the tissues.

Clinical Benefits

When used as part of a comprehensive treatment plan, Sodime offers several clinical benefits:

  • Reduction in Swelling: Effective management of edema can improve mobility and physical comfort for patients experiencing significant tissue swelling.
  • Cardiac Workload Reduction: By decreasing the total fluid volume, the medication reduces the workload on the heart, which is particularly beneficial for individuals with heart failure.
  • Blood Pressure Stability: Consistent use as directed helps maintain blood pressure within a target range, contributing to long-term vascular health.
  • Improved Symptom Management: For patients with fluid-related respiratory distress, the medication can help improve breathing capacity by clearing fluid from the pulmonary system.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Sodime

The official regulatory profile for Sodime (Ceftazidime) explicitly defines who is eligible for use, who is contraindicated, and which populations require restricted administration, based on government labeling.

Eligibility Scope Official Regulatory Status
Contraindicated Populations Individuals with a documented history of hypersensitivity to Ceftazidime, any other cephalosporin drug, or a severe allergic reaction to any other beta-lactam antibiotic (e.g., penicillin) must not use this medicine.
Established Use Use is established for adults and most pediatric patients for approved indications.
Age Restrictions Safety and effectiveness are not established for all approved uses in infants younger than three months. Older adults must be assessed for adequate renal function.

Condition-Specific Eligibility Rules Patients with impaired kidney function require restricted use because Sodime is eliminated almost entirely by the kidneys. Failure to account for reduced clearance can lead to increased drug levels. Use is also restricted, or requires caution, in patients with a history of colitis or pre-existing CNS disorders. No special adjustment is required for isolated hepatic impairment.

Pregnancy and Lactation Eligibility The drug’s use during pregnancy is restricted to situations where the potential benefit clearly warrants use. Use while lactating is generally considered acceptable, as only low levels pass into human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Sodime (Ceftazidime) is primarily eliminated unchanged by the kidneys and is not metabolized by major enzyme systems, defining a specific interaction profile documented in official regulatory labels.

Documented Pharmacological Interactions

The most critical regulatory constraint concerns combinations that increase the risk of nephrotoxicity. Co-administration with other medicines known to adversely affect renal function, such as aminoglycosides (e.g., Gentamicin) or potent diuretics (e.g., Furosemide), may increase the potential for kidney damage. This risk is notably heightened in patients with renal impairment, where slower drug clearance can lead to accumulation-related adverse events, including neurological issues.

A pharmacodynamic interaction is documented with Chloramphenicol, where in vitro studies showed antagonistic effects against Gram-negative bacteria. Therefore, this combination should be avoided when a full bactericidal effect is desired.

Administration and Laboratory Constraints

Physical incompatibility is a mandatory constraint for preparation: Sodime must not be mixed with aminoglycosides in the same intravenous solution due to the risk of precipitation. Furthermore, the medicine is known to cause interference with diagnostic tests, resulting in a false-positive reaction for glucose in the urine when using copper reduction methods and potentially causing a positive direct Coombs’ test.

Mechanism of Action

Irreversible Inhibition of Bacterial Cell Wall Synthesis

The mechanism of Sodime (Ceftazidime) acts by engaging a core mechanistic domain unique to bacteria: the final steps of cell wall construction. The molecule functions as an irreversible covalent inhibitor by binding specifically to bacterial enzymes called Penicillin-binding proteins (PBPs), particularly PBP3. This targeted blockade stops the enzymes from performing the essential transpeptidation (cross-linking) of the peptidoglycan strands, leading to a rapid loss of structural integrity.

Causal Cascade Leading to Bactericidal Lysis

This inhibition initiates a rapid mechanistic cascade resulting in a bactericidal (cell-killing) effect. With the cell wall critically compromised, the bacterial cell cannot withstand its internal osmotic pressure and ruptures (lysis). This sequence actively and physically destroys the structure of the bacterial cell, resulting in the destruction of the systemic bacterial load, which is the physiological consequence of the drug's mechanism.

Constraints on the Mechanism of Action

The drug's mechanism is biologically constrained by bacterial defense mechanisms, primarily the production of beta-lactamase enzymes that chemically destroy the drug before it reaches the target.

Dosage and Administration Information

Official Administration Guidelines for Oral Sodime

Sodime (immediate-release oral tablets and extended-release tablets) must be taken exactly as prescribed, using the lowest effective dose for the shortest duration necessary to treat insomnia. The use of this medicine is not recommended for children due to insufficient data on safety and efficacy.

Dosing and Administration

  • Timing: Take the tablet or capsule orally once per night immediately before bedtime when you are ready to go to sleep. Do not take it sooner.
  • Procedural Constraint: You must be able to remain in bed for a full 7 to 8 hours after taking the dose before the planned time of awakening. Taking it with less sleep time remaining can increase the risk of next-day impairment.
  • Food: For faster sleep onset, Sodime should not be taken with or immediately after a meal, as food may slow its effect.
  • Preparation: Swallow extended-release tablets and capsules whole. Do not open, divide, crush, or chew this form of the medication.

Dosing Guidelines (Immediate-Release Tablets)

Population Initial Dose (Once Daily) Maximum Dose (Per Day)
Adult Women 5 mg 10 mg
Adult Men 5 mg or 10 mg 10 mg
Older Adults 5 mg 5 mg

Initial doses differ by sex because the clearance of Sodime is generally slower in women. If a dose is missed, skip the missed dose and do not take a double dose; use the medication only when you cannot sleep.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sodime (Ceftazidime)

Research into Sodime, whose active ingredient is Ceftazidime, focuses primarily on its use against certain infections caused by Gram-negative bacteria. The evidence base is composed of controlled clinical trials, retrospective observational studies, and comprehensive scientific reviews that examined changes measured during the study period and microbiological responses across different hospital settings.


Evidence for Use in Complicated Urinary Tract Infections (cUTI) and Intra-Abdominal Infections (cIAI)

The evidence for Sodime in complicated urinary tract infections (cUTI) and intra-abdominal infections (cIAI) is largely derived from Randomized Controlled Trials (RCTs) and systematic meta-analyses. Researchers examined specific outcomes such as the rate of microbiological status, which monitors the status of bacterial presence at the infected site, and the clinical status at follow-up, which documents the change in the patient’s signs and symptoms.

In the case of intra-abdominal infections, the research often includes Sodime as part of a combination regimen alongside another antibiotic; this regimen was studied for its effects in patients with these infections. However, the evidence for Sodime monotherapy alone is more limited. Long-term effects are not fully established beyond the standard trial follow-up, and findings describing the patterns of response to Ceftazidime alone are continuously being supplemented by studies of combination products.


Evidence for Use in Severe Pneumonia, Bacteremia, and Sepsis

For severe systemic infections, the research is often structured around retrospective cohort studies and systematic reviews that draw evidence from clinical practice settings. These studies examined crucial outcomes related to physiological strain, such as all-cause mortality (death rates) within 30 days of treatment onset, and microbiological response in patients with documented Gram-negative pathogens, including Pseudomonas aeruginosa.

Because these patients often have high varying symptom burdens, the heterogeneity (variability) in study results is a factor. These limitations mean that the findings describe group patterns observed in the studies, and research does not determine whether an individual will respond similarly. Recent research increasingly explores combination therapies; this pattern is noted in the evidence base for Ceftazidime monotherapy.


Research Evidence for Use in Febrile Neutropenia

Sodime was evaluated in patients with febrile neutropenia, a condition involving fever in patients with a severely low white blood cell count. This research typically involves prospective comparative trials where the medicine was studied in research scenarios involving an unknown source of fever. The primary outcomes studies monitored were the patterns of fever change and the time it took for fever to subside in the observed populations. The follow-up durations were short-term, primarily covering the immediate episode of fever and neutropenia (typically 7 to 14 days).

Key Studies & References

  1. DailyMed Label for Ceftazidime (NLM - National Library of Medicine)
  2. Ceftazidime: an updated review of its antibacterial activity, pharmacokinetic properties and therapeutic use

Frequently Asked Questions (FAQ)

Common questions about Sodime (FAQ)


Q: How quickly does Sodime usually start working?

A: Sodime is classified to act immediately upon administration by disrupting bacterial cell wall synthesis. While the drug is working quickly at a microscopic level, patient improvement in signs and symptoms of infection typically begins within the first few days of treatment, according to clinical data.

Q: Can Sodime change my mood or energy levels?

A: Official safety documents include neurologic adverse reactions as documented potential effects. These can manifest as confusion, drowsiness, and unusual tiredness or weakness. Regulatory information advises caution for patients with pre-existing conditions affecting the Central Nervous System (CNS).

Q: What is the expected long-term outcome for people taking Sodime?

A: Sodime is used for short-term, acute infections. Research documentation explicitly states that long-term effects beyond the standard follow-up periods of the clinical trials are not fully established.

Q: Does Sodime interact with birth control pills?

A: Yes, official regulatory labeling documents that Sodime can decrease the effectiveness of some oral contraceptives (birth control pills). Regulatory documents state that using an additional or alternative form of birth control may be a necessary consideration during treatment.

Q: What are the main findings from the clinical trials of Sodime?

A: Clinical studies focused on severe bacterial infections, such as complicated urinary tract infections and pneumonia. Researchers primarily examined outcomes related to the rate of microbiological status, which monitors the presence of bacteria, and changes in the patient's clinical status following treatment.

Q: Is Sodime known to cause skin rashes or allergic reactions?

A: Hypersensitivity reactions, including skin rash, are documented adverse effects of Sodime. In formal clinical studies, these reactions were reported in less than 2% of patients.

Q: How does the effectiveness of Sodime change over time?

A: Effectiveness can be biologically constrained by bacterial defense mechanisms, which are always evolving. The development of bacterial resistance, such as through the production of beta-lactamase enzymes, is a known factor that can limit the drug's effectiveness over time.

Q: What is the typical duration of treatment with Sodime?

A: Sodime is generally used for short-term courses to manage acute, severe infections. Treatment is generally used for short-term courses, and the duration is determined by the specific infection being treated and the patient's clinical status.

Q: What happens if I stop taking Sodime suddenly?

A: Official guidance emphasizes that the full prescribed course of the medicine should be completed, even if symptoms improve quickly. Stopping treatment too soon or skipping doses can allow the infection to return and may also contribute to the bacteria becoming resistant to the antibiotic.

Q: Is Sodime considered a long-term medication?

A: No, Sodime is not classified as a long-term medication. It is used for short-term courses to eliminate acute, severe systemic bacterial infections within a defined treatment period.

Q: Does Sodime show up on drug tests?

A: Sodime is known to interfere with specific laboratory diagnostic tests. These interferences include a false-positive reaction for glucose in the urine when using copper reduction methods, and it may also cause a positive direct Coombs’ test.

Q: Is there a generic version of Sodime available?

A: Yes, the active ingredient in Sodime is Ceftazidime, which is widely available in generic form.

Q: Does alcohol interact negatively with Sodime?

A: According to the official product information, the specific interaction of this medicine with alcohol is currently unknown.

Q: Is it okay to drive or operate machinery while taking Sodime?

A: Because the medicine may be associated with Central Nervous System effects, including confusion, drowsiness, and dizziness, caution is advised when performing tasks such as driving or operating machinery.

Q: Is Sodime known to cause weight gain or weight loss?

A: Unusual weight loss is listed as a less common documented side effect. Weight gain is also listed among the possible side effects, but its incidence in clinical studies is noted as unknown.

Q: Does Sodime affect sleep patterns?

A: Yes, official adverse reaction profiles list both drowsiness and severe sleepiness as potential documented effects on the Central Nervous System.

Q: Why do some people say they feel 'off' when they first start Sodime?

A: The most frequent documented adverse reactions, which often occur at the start of treatment, include hypersensitivity reactions, gastrointestinal symptoms, and central nervous system reactions. These groupings were reported in less than 2% of patients during formal clinical studies.

Q: Is Sodime safe for elderly patients?

A: Official information indicates that older adults should be assessed for adequate kidney function before use. Since Sodime is eliminated primarily by the kidneys, reduced renal function can prolong the drug's clearance and increase the risk of serious adverse neurological reactions.

Q: Is there any research on Sodime use during pregnancy?

A: Animal reproduction studies have been conducted and showed no evidence of harm to the fetus. However, regulatory documents state there are no adequate and well-controlled studies conducted in pregnant women. Regulatory documents describe use as restricted to certain situations as determined by a healthcare professional.

Q: Do I need to get regular blood tests while on Sodime?

A: The medicine is associated with a potential for high-level safety consequences like prolonged prothrombin time (a measure of blood clotting). Monitoring of blood clotting factors is noted in regulatory information as a potential consideration, particularly for patients using blood thinners.

Q: Is Sodime meant to cure the condition or just manage symptoms?

A: Sodime is a bactericidal agent, meaning its function is to actively kill bacteria. Its purpose is to fight and eliminate severe systemic bacterial infections by directly destroying the bacterial structures.

Q: Can children or adolescents use Sodime?

A: Use is established for most pediatric patients, including adolescents, for approved indications. However, safety and effectiveness are not established for all approved uses in infants younger than three months.

Q: How long does Sodime stay in your system after the last dose?

A: For individuals with normal kidney function, the biological half-life of Ceftazidime is approximately 1.5 to 2 hours. Between 80% to 90% of a dose is typically excreted unchanged by the kidneys within 24 hours of administration.

Q: Can Sodime make existing mental health issues worse?

A: Caution is advised in patients with a history of pre-existing Central Nervous System (CNS) disorders. Reduced kidney function can increase the risk of serious neurologic adverse reactions, such as confusion and seizures.

Q: Is it typical for doctors to prescribe Sodime with another medication?

A: In research studies for conditions like complicated intra-abdominal infections, Sodime is often documented as being part of a combination regimen alongside another antibiotic.

Q: Can I take Sodime if I have high blood pressure?

A: High blood pressure (hypertension) is listed in regulatory documents as a moderate potential hazard interaction. Regulatory documents state that this medicine is associated with caution in patients with high blood pressure (hypertension) and professional assessment is indicated.

How should Sodime be stored and disposed of?

Official Storage and Disposal Requirements for Sodime

The official regulatory labeling for Sodime defines mandatory conditions for storage and disposal to ensure product quality and safety.

Requirement Area Official Statement (Regulatory Basis)
Storage Temperature Store below 25°C (77°F). Do not freeze.
Protection Keep in the original container to protect from light and moisture.
Child Safety Store out of the sight and reach of children.
In-Use Stability Discard any unused portion 28 days after first opening or reconstitution.
Disposal Do not dispose of via household waste or wastewater. Return unused or expired Sodime to a pharmacy or approved collection point.

These official statements ensure the medication maintains its chemical stability and efficacy until its expiry date. The mandated disposal rules are in place to prevent environmental contamination and accidental exposure.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sodime found in:

A-Z Index: